Page last updated: 2024-08-22

lutetium and mk-1775

lutetium has been researched along with mk-1775 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Béhé, M; Cohrs, S; Grünberg, J; Lindenblatt, D; Pellegrini, G; Schibli, R; Spycher, PR; Terraneo, N; Vukovic, D	1

Other Studies

1 other study(ies) available for lutetium and mk-1775

Article	Year
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. BMC cancer, 2018, Sep-25, Volume: 18, Issue:1 Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA Breaks, Double-Stranded; Female; Humans; Immunoconjugates; Lutetium; Mice; Neural Cell Adhesion Molecule L1; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrimidinones; Radioimmunotherapy; Radioisotopes; Xenograft Model Antitumor Assays	2018

Article

Year

Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.

BMC cancer, 2018, Sep-25, Volume: 18, Issue:1

Topics: Animals; Antineoplastic Agents, Immunological; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA Breaks, Double-Stranded; Female; Humans; Immunoconjugates; Lutetium; Mice; Neural Cell Adhesion Molecule L1; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrimidinones; Radioimmunotherapy; Radioisotopes; Xenograft Model Antitumor Assays

2018